Literature DB >> 20622810

Pharma embraces open source models.

Stephen Strauss.   

Abstract

Mesh：

Year:  2010        PMID： 20622810     DOI： 10.1038/nbt0710-631

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  6 in total

1.  Research at the interface of industry, academia and regulatory science.

Authors:  William B Mattes; Elizabeth Gribble Walker; Eric Abadie; Frank D Sistare; Jacky Vonderscher; Janet Woodcock; Raymond L Woosley
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908

Review 2.  Arguments against precompetitive collaboration.

Authors:  G Vargas; B Boutouyrie; S Ostrowitzki; L Santarelli
Journal:  Clin Pharmacol Ther       Date:  2010-05       Impact factor: 6.875

Review 3.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

4.  2 billion euro IMI launched with European pharma.

Authors:  John Hodgson
Journal:  Nat Biotechnol       Date:  2008-07       Impact factor: 54.908

5.  Thousands of chemical starting points for antimalarial lead identification.

Authors:  Francisco-Javier Gamo; Laura M Sanz; Jaume Vidal; Cristina de Cozar; Emilio Alvarez; Jose-Luis Lavandera; Dana E Vanderwall; Darren V S Green; Vinod Kumar; Samiul Hasan; James R Brown; Catherine E Peishoff; Lon R Cardon; Jose F Garcia-Bustos
Journal:  Nature       Date:  2010-05-20       Impact factor: 49.962

Review 6.  The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.

Authors:  J A Wagner; M Prince; E C Wright; M M Ennis; J Kochan; D J R Nunez; B Schneider; M-D Wang; Y Chen; S Ghosh; B J Musser; M T Vassileva
Journal:  Clin Pharmacol Ther       Date:  2010-05       Impact factor: 6.875
  6 in total
  4 in total

1.  Public-private partnerships need honest brokering.

Authors:  Michel Goldman
Journal:  Nat Med       Date:  2012-03-06       Impact factor: 53.440

2.  Drug repurposing: mining protozoan proteomes for targets of known bioactive compounds.

Authors:  Adam Sateriale; Kovi Bessoff; Indra Neil Sarkar; Christopher D Huston
Journal:  J Am Med Inform Assoc       Date:  2013-06-11       Impact factor: 4.497

Review 3.  Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?

Authors:  Alexander Schuhmacher; Oliver Gassmann; Nigel McCracken; Markus Hinder
Journal:  J Transl Med       Date:  2018-05-08       Impact factor: 5.531

Review 4.  Changing R&D models in research-based pharmaceutical companies.

Authors:  Alexander Schuhmacher; Oliver Gassmann; Markus Hinder
Journal:  J Transl Med       Date:  2016-04-27       Impact factor: 5.531
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.